5 assets in Anal Margin Squamous Cell Carcinoma

Therapeutic assets addressing Anal Margin Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Nivolumab Anal Margin Squamous Cell Carcinoma	National Cancer Institute (NCI)	P3	BB (64)
Capecitabine Anal Margin Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Fludeoxyglucose Anal Margin Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Fluorouracilum Anal Margin Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Muamycin Anal Margin Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)